{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:06:30Z","timestamp":1790856390405,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Berlin-Chemie"},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"name":"InterMune"},{"DOI":"10.13039\/100006259","name":"Teva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministry of Education and Science"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012416","name":"Inova Fairfax Health System, Miller Communications, the National Association for Continuing Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001465","name":"American Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006474","name":"Columbia University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006474","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006732","name":"New York University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CMC"},{"DOI":"10.13039\/100007472","name":"UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007472","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007472","name":"UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007472","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.rmed.2019.08.010","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T20:20:51Z","timestamp":1566505251000},"page":"59-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["A phase III study of triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler 320\/18\/9.6\u202f\u03bcg and 160\/18\/9.6\u202f\u03bcg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol"],"prefix":"10.1016","volume":"158","author":[{"given":"Klaus F.","family":"Rabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2412-3182","authenticated-orcid":false,"given":"Fernando J.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary T.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7857-5435","authenticated-orcid":false,"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga A.","family":"Wedzicha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopa","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Earl","family":"St Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaila","family":"Ballal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"McLaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Darken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Reisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dorinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10048","key":"10.1016\/j.rmed.2019.08.010_bib1","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet (London, Engl)"},{"issue":"4","key":"10.1016\/j.rmed.2019.08.010_bib2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","article-title":"FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease","volume":"196","author":"Lipson","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10082","key":"10.1016\/j.rmed.2019.08.010_bib3","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","article-title":"Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet (London, Engl)"},{"issue":"18","key":"10.1016\/j.rmed.2019.08.010_bib4","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10125","key":"10.1016\/j.rmed.2019.08.010_bib5","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet (London, Engl)"},{"issue":"10","key":"10.1016\/j.rmed.2019.08.010_bib6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"Ferguson","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"23","key":"10.1016\/j.rmed.2019.08.010_bib7","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.rmed.2019.08.010_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/rccm.201803-0405OC","article-title":"Long-term triple therapy De-escalation to indacaterol\/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-Dummy clinical trial","volume":"198","author":"Chapman","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"14","key":"10.1016\/j.rmed.2019.08.010_bib9","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","article-title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","volume":"371","author":"Magnussen","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.rmed.2019.08.010_bib10","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","article-title":"Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial","volume":"4","author":"Watz","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2019.08.010_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(18)30006-7","article-title":"Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials","volume":"6","author":"Bafadhel","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"6","key":"10.1016\/j.rmed.2019.08.010_bib12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2019.08.010_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00164-2019","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019","volume":"53","author":"Singh","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2019.08.010_bib14","series-title":"Inhaled Corticosteroids (ICS) Containing Medicinal Products Indicated in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)","author":"European Medicines Agency","year":"2016"},{"issue":"11","key":"10.1016\/j.rmed.2019.08.010_bib15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/thoraxjnl-2012-202872","article-title":"Inhaled corticosteroids in COPD and the risk of serious pneumonia","volume":"68","author":"Suissa","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2019.08.010_bib16","first-page":"CD010115","article-title":"Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease","volume":"3","author":"Kew","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.rmed.2019.08.010_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1513\/AnnalsATS.201409-413OC","article-title":"Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD","volume":"12","author":"Crim","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"9691","key":"10.1016\/j.rmed.2019.08.010_bib18","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0140-6736(09)61250-2","article-title":"Budesonide and the risk of pneumonia: a meta-analysis of individual patient data","volume":"374","author":"Sin","year":"2009","journal-title":"Lancet (London, Engl)"},{"key":"10.1016\/j.rmed.2019.08.010_bib19","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2147\/COPD.S177333","article-title":"Current appraisal of single inhaler triple therapy in COPD","volume":"13","author":"Lipworth","year":"2018","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"3","key":"10.1016\/j.rmed.2019.08.010_bib20","doi-asserted-by":"crossref","first-page":"1801334","DOI":"10.1183\/13993003.01334-2018","article-title":"Budesonide\/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study","volume":"52","author":"Ferguson","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2019.08.010_bib21","series-title":"Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects with Moderate to Very Severe COPD (Ethos)","author":"ClinicalTrials.gov","year":"2017"},{"issue":"8","key":"10.1016\/j.rmed.2019.08.010_bib22","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.rmed.2008.04.019","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50 \u03bcg) or salmeterol (50 \u03bcg) on COPD exacerbations","volume":"102","author":"Ferguson","year":"2008","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2019.08.010_bib23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/15412550903140881","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50) on COPD exacerbations and impact on patient outcomes","volume":"6","author":"Anzueto","year":"2009","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2019.08.010_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.rmed.2018.03.016","article-title":"Blood eosinophil levels as a biomarker in COPD","volume":"138","author":"Brusselle","year":"2018","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2019.08.010_bib25","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1183\/13993003.01370-2015","article-title":"Blood eosinophils as a marker of response to inhaled corticosteroids in COPD","volume":"47","author":"Barnes","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2019.08.010_bib26","series-title":"Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease","author":"ClinicalTrials.gov","year":"2018"},{"key":"10.1016\/j.rmed.2019.08.010_bib27","series-title":"Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects with COPD Compared with Symbicort\u00ae Turbohaler\u00ae","author":"ClinicalTrials.gov","year":"2017"},{"issue":"1","key":"10.1016\/j.rmed.2019.08.010_bib28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12931-019-1126-7","article-title":"Bone and ocular safety of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study","volume":"20","author":"Kerwin","year":"2019","journal-title":"Respir. Res"},{"issue":"1","key":"10.1016\/j.rmed.2019.08.010_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4104\/pcrj.2012.00092","article-title":"Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD","volume":"22","author":"Price","year":"2013","journal-title":"Prim. Care Respir. J."},{"issue":"6","key":"10.1016\/j.rmed.2019.08.010_bib30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M15-0288","article-title":"Good publication practice for communicating company-sponsored medical research: GPP3","volume":"163","author":"Battisti","year":"2015","journal-title":"Ann. Intern. Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119302677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611119302677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:58:53Z","timestamp":1760615933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611119302677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":30,"alternative-id":["S0954611119302677"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2019.08.010","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase III study of triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler 320\/18\/9.6\u202f\u03bcg and 160\/18\/9.6\u202f\u03bcg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2019.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}